METex14 ctDNA Dynamics & Resistance Mechanisms Detected in Liquid Biopsy (LBx) From Patients (pts) With METex14 Skipping NSCLC Treated With Tepotinib
P. Paik(Memorial Sloan Kettering Cancer Center), Xiao‐Feng Le(The University of Texas MD Anderson Cancer Center), Andreas Johne(Merck KGaA, Darmstadt (Germany)), Wade T. Iams(Vanderbilt University Medical Center), Christopher Stroh(Universität Hamburg), PierFranco Conte(University of Padua), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Julien Mazières(Université Toulouse III - Paul Sabatier), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), R. O'Hara(Cornell University), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Antoine Cortot(Centre Hospitalier Universitaire de Lille), Hiroya Sakai(Saitama Cancer Center), Marina Chiara Garassino(University of Chicago), Michael Thomas, Jürgen Scheuenpflug(Merck KGaA, Darmstadt (Germany)), E. Felip(Vall d'Hebron Institute of Oncology), Jo Raskin(Inserm)
International Journal of Radiation Oncology*Biology*Physics
January 6, 2022
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k